CytoSorbents reports Q4 revenue growth via Investing.com

PRINCETON, NJ – CytoSorbents Corporation (NASDAQ: CTSO ), a medical device company specializing in hemodialysis with a market capitalization of $50.31 million, announced preliminary financial results for the fourth quarter and full year of 2024. According to InvestingPro data, the…

Innovent Wins China Drug Award Nuvation Bio (NUVB:NYSE)

kemalbas/iStock via Getty Images Innovent Biologics (OTCPK:IVBIY) announced that Chinese regulators approved its second marketing application for lung cancer therapy, Dovbleron, developed with US biotech Nuvation Bio (NYSE:NUVB). The Chinese biotech company announced late Thursday that China's National Medical Products…